Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma

Figure 2 Viability (± SE) of OE33P and OE33R cells were assessed using a cell counting kit-8 assay with or without radiation (n = 3). Ionising radiation with immune checkpoint blockade results in a greater reduction in cell viability when compared to either modality alone. Graph shows % expression (± SE). A: Treatment with radiation dosing only; B: Treatment with radiation and single agent immunotherapy Atezolizumab; C: Treatment with radiation and single agent immunotherapy Pembrolizumab; D: Treatment with radiation and single agent immunotherapy Nivolumab; E: Treatment with radiation and dual immunotherapy agents Atezolizumab & Pembrolizumab; F: Treatment with radiation and dual immunotherapy agents Atezolizumab & Nivolumab. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 paired t-test; ^dP < 0.05, ^eP < 0.01, ^fP < 0.001 unpaired t-test.